Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Crinetics Pharmaceuticals by Year
Crinetics Pharmaceuticals — Stock-based compensation expense ($M) ($M)
Vertex Pharmaceuticals Crinetics Pharmaceuticals: $91.0M in FY2025, up 31.2% from a year earlier. That is the highest of the 8 years on record here.
Where the FY2025 figure comes from
Source: SEC Filing ↗
Reported in SEC XBRL (CIK 0001699813 Crinetics Pharmaceuticals).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Crinetics Pharmaceuticals — Stock-based compensation expense ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 91.0 | +31.2% | SEC Filing ↗ |
| FY2024 | Dec 31, 2024 | 69.4 | +69.5% | SEC Filing ↗ |
| FY2023 | Dec 31, 2023 | 40.9 | +44.8% | SEC Filing ↗ |
| FY2022 | Dec 31, 2022 | 28.3 | +62.9% | SEC Filing ↗ |
| FY2021 | Dec 31, 2021 | 17.4 | +66.3% | SEC Filing ↗ |
| FY2020 | Dec 31, 2020 | 10.4 | +65.8% | SEC Filing ↗ |
| FY2019 | Dec 31, 2019 | 6.29 | +171.1% | SEC Filing ↗ |
| FY2018 | Dec 31, 2018 | 2.32 | – | SEC Filing ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals Crinetics Pharmaceuticals ($M), annual FY2018–FY2025 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/crinetics-sbc-exp
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.